Results 161 to 170 of about 83,183 (296)

Believing in the Nobel Prize: Long-term Success After HLA-Identical Kidney Transplantation in 3 Monozygotic Twins Without any Induction or Maintenance Immunosuppression. [PDF]

Transplant Direct
Akifova A, Ömeroğlu ÖE, Halleck F, Osmanodja B, Schrezenmeier EV, Bachmann F, Stauch D, Lachmann N, Budde K.   +8 more
europepmc   +1 more source

Development and analytical validation of a targeted short‐read next generation sequencing‐based pharmacogenetic panel for comprehensive variant detection

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Genomic profiling of patients for genetic variants that modify the effect of specific medications has many benefits, including the possibility of avoiding toxicities and ensuring an adequate effect of the medication. Our intention was to develop a comprehensive, high‐quality pharmacogenetic test panel for clinical use ...
Anna Gréen, Nils Johan Fredriksson, Michael Andresen, Jon Jonasson, Malin Lindqvist Appell, Henrik Gréen   +5 more
wiley   +1 more source

HLA-A*02:1227 and HLA-A*36:16N, Two Novel HLA-A Alleles Identified in Brazilian Bone Marrow Donors. [PDF]

HLA
Dos Santos Júnior ACS, de Oliveira CKF, Fabreti-Oliveira RA.   +2 more
europepmc   +1 more source

SLPI/FBW7/c‐Myc Axis Reduces Gemcitabine Sensitivity in PDAC by Enhancing Glycolysis and Impairing NK Cell Immunity

Cancer Science, EarlyView.
SLPI reduces the sensitivity of PDAC to gemcitabine by competing with FBW7 for binding to c‐Myc, thereby disrupting FBW7‐dependent ubiquitination and proteasomal degradation of c‐Myc, leading to increased c‐Myc stability and expression. SLPI knockdown could significantly increase gemcitabine sensitivity to gemcitabine‐induced direct cytotoxicity and NK
Haofei Chen, Xin Li, Weixiong Zhu, Yanxi Mu, Guoqing Zhang, Youheng Zhang, Yusheng Cheng, Wence Zhou   +7 more
wiley   +1 more source

A new path to spillover: MHC-II entry of influenza A viruses. [PDF]

PLoS Biol
Stertz S, Karakus U.
europepmc   +1 more source

Docetaxel‐Induced Immune Activation Shows Antitumor Synergy With the Tumor‐Targeted CD40 Agonist KK2269

Cancer Science, EarlyView.
CD40 agonists have demonstrated proof‐of‐concept for converting an immunologically cold tumor into a hot tumor in preclinical studies; however, clinically, they have shown limited antitumor efficacy as monotherapy. We tested a tumor‐targeted CD40 agonist, KK2269 (a bispecific antibody that binds to CD40 and EpCAM), in combination with various ...
Yuta Tezuka, Kyoko Kawasaki, Yoshiki Sumitomo, Masato Saito, Akari Yao, Munetoshi Ando   +5 more
wiley   +1 more source

Non-HLA Genetics and Application to Living Donor Candidates. [PDF]

Curr Transplant Rep
Caliskan Y, Afsar B, Afsar RE, Varma C, Aygormez O, Lentine KL.   +5 more
europepmc   +1 more source

Milestones in Transplantation: The Story so Far [PDF]

, 2001
Starzl, TE
core  

Autophagy Inhibition by Fangji Huangqi Decoction Enhances Tumor Immunogenicity and Potentiates PD‐1 Blockade

Cancer Science, EarlyView.
In tumor cells, MHC‐I is typically degraded through autophagy, leading to reduced antigen presentation. However, Fangji Huangqi Decoction (FJHQ), acting as an autophagy inhibitor, suppresses lysosomal acidification, which in turn inhibits the degradation of MHC‐I. This results in increased surface expression of MHC‐I on tumor cells.
Yuxiao Jiang, Shiji Zeng, Dingye Wang, Junbo Jiang, Zhenzhen Li, Jingbi Li, Dan Chen, Xu Zhao, Zheng Ying, Yuehua Deng, Qianwei Cai, Silin Mai, Jiayi Zheng, Qiaohong Yang, Fang Liu, Biaoyan Du, Jianyong Xiao, Xiaoyi Liu, Kun Wang   +18 more
wiley   +1 more source

Recommendations for HLA Genotyping Data Standards and Clinical Laboratory Staffing Considerations. [PDF]

HLA
Spierings E, Brown NK, Latham K, Robinson J, Melchers M, Askar M, Morris GP, Weimer E, Maiers M, Madbouly A.   +9 more
europepmc   +1 more source